Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Harbour BioMed

Tracked across 3 events · 19 articles · First seen Jun 10, 2026 · Last active Jun 15, 2026

Sentiment
57
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 60
Business
Impact: Harbour BioMed's IND application for HBM7004 has been accepted by the China — National Medical Products Administration (NMPA) of China, which is a positive step towards clinical evaluation in China and could enhance its market position in oncology therapeutics.
Jun 10, 2026 · 7 articles
2 40
Business
Impact: Harbour BioMed appointed Dhavalkumar Patel>>> as a Scientific Advisor, which is expected to enhance its immunology pipeline and drug development capabilities.
Jun 12, 2026 · 6 articles
4 70
Business
Impact: Harbour BioMed secured a complete victory in its patent infringement lawsuit against Amgen and Teneobio, validating its proprietary transgenic rodent technology and entitling it to $20.2 million in damages, with potential for up to $60.6 million. This strengthens its position as an innovator in the antibody technology field.
Jun 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Harbour BioMed live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.